• Senescence Gene Signatures Enable Early AAA Diagnosis and In

  2026-05-09

  This study identifies ETS1 and ITPR3 as senescence-related gene biomarkers for early, noninvasive diagnosis of abdominal aortic aneurysm (AAA). Using machine learning and multi-cohort validation, the work clarifies the link between cellular senescence and AAA progression, offering new directions for therapeutic intervention and preclinical modeling.

• Exosomal SNORD52 Drives M2 Macrophage Polarization via JAK2/

  2026-05-08

  This article reviews new evidence that hepatoma cell-derived exosomal SNORD52 promotes M2 macrophage polarization through activation of the JAK2/STAT6 pathway in hepatocellular carcinoma (HCC). The findings provide a mechanistic link between tumor exosomal communication and immune microenvironment modulation, highlighting new avenues for targeted cancer immunotherapy.

• LG 101506 and RXR Modulation: Next-Gen Strategies in Transla

  2026-05-08

  This thought-leadership article dissects the mechanistic and translational impact of LG 101506, a high-purity RXR modulator from APExBIO, in the context of nuclear receptor signaling and cancer immune evasion. By connecting recent discoveries in PD-L1 regulation and triple-negative breast cancer (TNBC) immunotherapy with advanced chemical biology tools, we provide strategic, evidence-driven guidance for translational researchers aiming to unlock new therapeutic avenues.

• Oxaliplatin: Applied Protocols and Resistance Solutions in C

  2026-05-07

  Oxaliplatin stands out as a platinum-based chemotherapeutic agent with robust efficacy across diverse cancer models, yet resistance remains a critical barrier. This article distills the latest experimental workflows, data-driven troubleshooting, and actionable strategies—empowering researchers to maximize translational impact and overcome chemotherapy resistance.

• Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast

  2026-05-07

  The referenced study uncovers how simultaneous inhibition of BRD4 and RAC1 disrupts the c-MYC-G9a-FTH1 pathway, suppressing growth and stemness in diverse breast cancer subtypes. This mechanistic insight highlights the therapeutic potential of epigenetic axis targeting and underscores the importance of G9a histone methyltransferase inhibition for cancer biology research.

• Doxorubicin in Cancer Research: Applied Workflows & Troubles

  2026-05-06

  Doxorubicin (Adriamycin) stands as a gold-standard chemotherapeutic agent for solid tumors and hematologic malignancies, offering reproducible cytotoxicity and apoptosis induction in cancer research. This article delivers optimized, evidence-backed workflows and troubleshooting strategies that maximize Doxorubicin’s translational impact, integrating insights from cutting-edge studies and APExBIO’s product expertise.

• Lenalidomide (CC-5013): Workflow Innovations in Myeloma Rese

  2026-05-06

  Lenalidomide (CC-5013) is redefining experimental strategies in multiple myeloma research through its immune-activating and angiogenesis-inhibiting properties. This guide delivers a protocol-driven, troubleshooting-focused roadmap, highlighting advanced applications and new synergies from cutting-edge epigenetic research.

• PD 173074: Translating FGFR/VEGFR Inhibition Into Oncology I

  2026-05-05

  Explore how PD 173074, a potent FGFR1/VEGFR2 inhibitor, is transforming translational cancer research by targeting tumor–stromal crosstalk, overcoming drug resistance, and enhancing the reproducibility of mechanistic studies. Anchored by the latest evidence from Saito et al. (2015) and scenario-driven laboratory guidance, this article offers strategic insights for researchers seeking to optimize experimental design and accelerate the path from discovery to impact.

• PPAR-α Activation Links Linoleic Acid to Tumor Progression i

  2026-05-05

  This study uncovers how linoleic acid promotes tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC) by upregulating tissue factor expression via PPAR-α activation. The findings highlight a previously uncharacterized metabolic-immune interplay and suggest new therapeutic targets for this rare lung cancer subtype.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-05-04

  This study introduces a patient-derived gastric cancer assembloid model integrating matched tumor organoids and stromal cell subpopulations. By recapitulating tumor microenvironment heterogeneity, the model enables nuanced analysis of drug response and resistance mechanisms, providing a more predictive platform for personalized therapy development.

• Imatinib (STI571): Precision Tools for Advanced Signal Trans

  2026-05-04

  Imatinib (STI571) revolutionizes cancer biology and signal transduction research by enabling highly selective and quantitative modulation of PDGF receptor, c-Kit, and Abl kinase pathways. Its robust inhibition profile and synergy with emerging hypoxia-targeted therapies empower researchers to dissect tumor microenvironments and resistance mechanisms with unprecedented fidelity.

• ER-Fusogenic Immunogenic Liposomes for Enhanced Cancer Vacci

  2026-05-03

  This study introduces phosphatidylinositol-based immunomodulatory nanoliposomes (PI-INLs) capable of simultaneously activating dendritic cells and directing antigens to the endoplasmic reticulum, thereby amplifying CD8 T cell responses for anti-tumor vaccination. The dual mechanism demonstrates a paradigm shift in nanovaccine design by achieving potent cellular immunity without synthetic adjuvants.

• SEC-seq Reveals VEGF-A Secretion Heterogeneity in MSCs

  2026-05-02

  The SEC-seq method enables simultaneous, single-cell quantification of protein secretion and transcriptomes in mesenchymal stromal cells (MSCs). By uncovering heterogeneous VEGF-A secretion and its weak correlation with VEGFA mRNA, the study provides a new window into functional cell state diversity and advances strategies for therapeutic cell selection.

• Small Molecule Inhibitors of Shh/Heparin Interactions: Funct

  2026-05-01

  Lamson et al. identified and characterized novel small molecule antagonists that disrupt Sonic hedgehog (Shh) binding to heparin, revealing a new regulatory point in Hedgehog signaling. Their findings advance understanding of Shh ligand-receptor dynamics and provide tools for dissecting pathway activation distinct from Smoothened agonists, with practical implications for developmental and disease model research.

• Oxaliplatin: Applied Workflows in Tumor Assembloid Drug Test

  2026-05-01

  Oxaliplatin, a platinum-based chemotherapeutic agent, empowers researchers to model clinically relevant drug responses using advanced tumor assembloid platforms. This article provides actionable protocols, troubleshooting insights, and expert perspectives on leveraging Oxaliplatin for translational cancer research.

15267 records 1/1018 page Next 12345 下5页 Last page